Download PDF
Thromb Haemost 1999; 82(05): 1433-1436
DOI: 10.1055/s-0037-1614850
Rapid Communications
Schattauer GmbH

Elevated Levels of sE-selectin in Post-menopausal Females Are Decreased by Hormone Replacement Therapy to Levels Observed in Pre-menopausal Females

Gwen Kennedy
2   National Heart and Lung Institute, Imperial College School of Medicine, Charing Cross Hospital, London, UK
,
Margaret McLaren
2   National Heart and Lung Institute, Imperial College School of Medicine, Charing Cross Hospital, London, UK
,
Jill J. F. Belch
2   National Heart and Lung Institute, Imperial College School of Medicine, Charing Cross Hospital, London, UK
,
Mary Seed
1   From the Section of Vascular Medicine and Biology, University Department of Medicine, Ninewells Hospital & Medical School, Dundee, and the National Heart and Lung Institute, Imperial College School of Medicine, Charing Cross Hospital, London, UK
› Author Affiliations
Further Information

Publication History

Received 06 November 1998

Accepted after resubmission 07 July 1999

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Summary

Observational epidemological studies have shown that mortality from coronary heart disease is reduced in post-menopausal women by hormone replacement therapy (HRT). The aim of this study was to measure sE-selectin levels in post-menopausal females before and after HRT and to compare these with pre-menopausal females and aged matched males. Post-menopausal females (n = 70) were given HRT or no treatment to act as a control group. sE-selectin levels were significantly lower in the pre-menopausal (n = 36) when compared with the post-menopausal females (n = 70) (p = 0.027), whereas no difference between two age matched male groups was found (n = 40). Oral and transdermal HRT significantly decreased sE-selectin levels (p <0.0001 and p = 0.0005 respectively) with no change in the control group. The reduction in the levels of this marker of endothelial activation after HRT, may reflect a decrease in leucocyte/endothelial interaction which may reduce atherosclerotic risk in post-menopausal females.

Keywords

E-selectin - atherosclerosis - hormone replacement therapy - endothelium - leucocyte
 

  • References

  • 1 Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 1997; 78 (10) 770-80.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17 beta estradiol on cytokine induced endothelial cell adhesion molecule expression. J Clin Invest 1996; 98: 336-42.
    CrossrefPubMedGoogle Scholar
  • 3 Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rfkind BM. Cardiovascular mortality and noncontraceptive use of oestrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-9
    CrossrefPubMedGoogle Scholar
  • 4 Newnham HH, Burger HG. Lipids, atherosclerosis, and postmenopausal hormone replacement therapy. In ‘Clinical Management of the Menopause’. Wren BC, Nachtigall L. (Eds) McGraw-hill Book Company; Sydney: 1996
    Google Scholar
  • 5 Sarrel PM. Hormone replacement therapy in the menopause. Int J Fertil Womens Med 1997; 42 (02) 78-84.
    PubMedGoogle Scholar
  • 6 Seed M, Crook D. Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. Curr Opin Lipidol 1994; 5: 48-58.
    CrossrefPubMedGoogle Scholar
  • 7 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/ progestin Replacement Study (HERS) Research Group. JAMA 1998; 280 (07) 605-13.
    CrossrefPubMedGoogle Scholar
  • 8 Grodstein F, Stamper MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med 1997; 336: 1769-75.
    CrossrefPubMedGoogle Scholar
  • 9 Faruqi RM, DiCorleto PE. Mechanisms of monocyte recruitment and accumulation. Br Heart J 1993; 69: 19-29.
    CrossrefPubMedGoogle Scholar
  • 10 Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OL, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
    CrossrefPubMedGoogle Scholar
  • 11 Kuijpers TW, Harlan JM. Monocyte-endothelial interactions: insights and questions. J Lab Clin Med 1993; 122: 641-51.
    PubMedGoogle Scholar
  • 12 Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993; 14: 506-12.
    CrossrefPubMedGoogle Scholar
  • 13 Smith CW. Potential significance of circulating E-selectin. Circulation 1997; 95: 1986-8.
    CrossrefPubMedGoogle Scholar
  • 14 Kirk G, Elhadd TA, McLaren M, Greene SA, Belch JJF. Children and adolescents with diabetes mellitus have higher soluble E-selectin and ICAM-1 levels than matched controls. Thromb Haemost 1997; Supplement 142 (abstract).
    PubMedGoogle Scholar
  • 15 Belch JJF, Shaw JW, Kirk G, McLaren M, Robb R, Maple C, Morse P. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. Circulation 1997; 95: 2027-31.
    CrossrefPubMedGoogle Scholar
  • 16 McCrohon JA, Adams MR, McCredie RJ, Robinson J, Pike A, Abbey M, Keech AC, Celermajer DS. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol Oxf 1996; 45: 435-41.
    CrossrefPubMedGoogle Scholar
  • 17 Maple C, Kirk G, McLaren M, Veale D, Belch JJF. A circadian variation exists for plasma levels of intercellular adhesion molecule-1 and E-selectin in healthy volunteers. Clin Sci 1998; 94 (05) 537-40.
    CrossrefPubMedGoogle Scholar
  • 18 Bridges AB, McLaren M, Pringle T, McNeil G, Belch JJF. Endothelial dysfunction in acute myocardial infarction following reperfusion. Am Heart J 1993; 126: 452-3.
    CrossrefPubMedGoogle Scholar
  • 19 Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 764-71.
    CrossrefPubMedGoogle Scholar
  • 20 Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch Intern Med 1996; 156: 1693-1700.
    CrossrefPubMedGoogle Scholar
  • 21 Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer Fe, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
    CrossrefPubMedGoogle Scholar
  • 22 Yamada K, Hayashi T, Kuzuya M, Naito M, Asai K, Iguchi A. Physiological concentration of 17 beta-estradiol inhibits chemotaxis of human monocytes in response to monocyte chemotactic peptide-1. Artery 1996; 22 (01) 24-35.
    PubMedGoogle Scholar
  • 23 Frazier-Jessen MR, Kovacs EJ. Estrogen modulation of JE/monocyte chemoattractant protein-1 mRNA expression in murine macrophages. J Immunol 1995; 154: 1838-45.
    PubMedGoogle Scholar
  • 24 Kirk G, McLaren M, Muir AH, Stonebridge PA, Belch JJF. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med 1999; 4: 23-6.
    CrossrefPubMedGoogle Scholar
  • 25 Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maturitas 1990; 12: 321-31.
    CrossrefPubMedGoogle Scholar